Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» ArQule shares rise after committee say liver cancer study can continue with lower drug dose
ArQule shares rise after committee say liver cancer study can continue with lower drug dose
ArQule shares rise after committee say liver cancer study can continue with lower drug dose
Submitted by
admin
on January 17, 2014 - 8:39am
Source:
Yahoo/AP
News Tags:
Arqule
liver cancer
FDA
tivantinib
Headline:
ArQule shares rise after committee say liver cancer study can continue with lower drug dose
Do Not Allow Advertisers to Use My Personal information
